BioNTech SE ADR (BNTX) dropped 4.79% after reporting that its Phase 2/3 trial for the mRNA cancer immunotherapy BNT113 failed to meet the first dual primary endpoint. The down move is supported by ...
BioNTech SE ADR (BNTX) jumped 4.52% after expanding its oncology pipeline with more late-stage cancer drugs, a move that is broadening investor focus beyond vaccines. The rebound looks limited, ...
BioNTech SE ADR (BNTX) fell 7.85% after the company terminated a Phase 2 clinical trial for its individualized mRNA cancer immunotherapy in colorectal cancer, triggering a rapid reversal of ...
Global markets are balancing fresh geopolitical stress with major corporate moves across technology and finance. Tensions around the Middle East and the NATO Summit are keeping energy supply risks ...
BioNTech (BNTX) stock is trading at $93.05, down 1.28% on the day, and is currently positioned above its key short- and medium-term moving averages but remains below the ...